CTI Clinical Trial & Consulting Services Announces Formation of Swedish Canadian Subsidiaries and Office
[Cincinnati, OH ~ November 5, 2015]
CTI Clinical Trial and Consulting Services (CTI), a multi-national, privately held, full-service contract research organization announces that it has opened an office in Stockholm, Sweden. The office is opened through the wholly-owned subsidiary, Clinical Trial and Consulting Services Sweden AB. The company has opened more than a dozen offices over the past few years, with additional international expansion planned for 2016.
“We have been conducting studies in Sweden with our own staff for many years, and felt that our international growth necessitated a physical presence in the country to better serve our pharmaceutical and biotechnology clients,” states Patrick Earley, Vice President, International.
Additionally, the company has started a wholly-owned subsidiary in Canada, CTI Clinical Trial & Consulting Services Canada ULC, with plans for an office in the future. According to Earley, “This new subsidiary shows CTI’s commitment to the high quality of research in Canadian hospitals and universities, as well as enables our sponsors to take advantage of research tax incentives that are provided by the government.”
CTI has been working for seventeen years in the drug development industry across North America, Europe, South America, Pac-Asia, and Africa, specializing in clinical research programs involving critically ill patient populations, and has more than 25 offices worldwide to serve nearly 100 pharmaceutical, biotechnology, and medical device clients.
About CTI Clinical Trial and Consulting Services
CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO), delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology, and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hepatology, cardiopulmonary, and pediatric populations. CTI also offers a fully integrated multi-specialty clinical research site that conducts phase I-IV trials. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. With clinical trial experience across 6 continents, CTI partners with research sites, patients, and sponsors to fulfill unmet medical needs. CTI is headquartered in Cincinnati, OH, with operations across North America, Europe, Latin America, and Asia-Pacific. For more information visit www.ctifacts.com
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
